南明哲 李冬冬

[摘要] 目的 探讨灯盏生脉胶囊在缺血性脑卒中患者二级预防中的疗效。方法 整群选取2014年2月—2015年3月在该院神经内科收治的126例缺血性脑卒中恢复期患者采用随机数字表法分为对照组（n=63）和观察组（n=63），两组患者均参照指南给予常规基础治疗口服阿司匹林肠溶片100 mg，1次/d，对阿司匹林不能耐受者可口服氯吡格雷75 mg，1次/d，连续治疗6个月；观察组在此基础上给予灯盏生脉胶囊治疗，2粒/次，3次/d，疗程为6个月。6个月后对照分析两组的神经功能恢复状况（NIHSS）、日常生活活动能力（Barthel指数）、运动功能（FMI）、致残率（mRS）、病死率、生存质量（SS-QOL）、复发率、纤维蛋白原（Fbi）及血脂等指标。结果 随访6个月后，观察组患者治疗后的NIHSS评分（9.08±4.37）、Barthel指数（88.36±18.68）、FMI评分（89.51±21.37）、SS-QOL（398.25±78.54）评分、血浆Fib（3.27±0.51）g/L、TC（5.27±0.82）mmo/L、TG（2.32±0.37）mmo/L和LDL-C（2.39±0.37）mmo/L均显著低于治疗前（P<0.05），而观察组明显低于对照组（P<0.05）；两组治疗后的mRS评分（1.16±1.25）明显低于治疗前（P<0.05），但组间比较差异无统计学意义（P>0.05）；两组患者治疗前后的HDL-C（1.29±0.41）mmo/L比较差异无统计学意义（P>0.05）；两组的复发率和病死率比较差异无统计学意义（P>0.05）。结论 缺血性脑卒中患者采用灯盏生脉胶囊联合西药进行二级预防，效果明显优于单纯西药。

[关键词] 灯盏生脉胶囊；缺血性脑卒中；二级预防；效果

[中图分类号] R74 [文献标识码] A [文章编号] 1674-0742（2016）03（c）-0146-04

Application Effects on the Seeondary Prevention for Isehemic Stroke by Erigeron Shengmai Capsule

NAN Ming-zhe，LI Dong-dong

Department of internal medicine，Jilin Central Hospital，Jilin，Jilin Province，132011 China

[Abstract] Objective To study the effects on the seeondary prevention for isehemic stroke by Erigeron Shengmai capsule. Methods 126 patients with isehemic stroke were randomly divided into routine control group（n=63）and observation group（n=63）. Two groups were given regular basis treatment with reference guide，observation group was given Erigeron Shengmai capsule，2/time，3 times/d，these drugs were continuous treatment for 6 months. Neurologic recovery state （NIHSS），daily life activities ability （Barthel index） ，motor function （FMI）， morbidity （mRS），mortality，quality of life （SS-QOL），recurrence rate，fibrinogen（Fbi） and blood lipids of control group and observation group were compared after treatment for 6 months. Results NIHSS score，Barthel index，FMI score，SS-QOL score，plasma Fib，TC，TG and LDL-C of two groups were significantly lower than before treatment（P<0.05），but those of observation group were significantly lower than the control group （P<0.05）. mRS score of two groups after treatment were significantly lower than before treatment（P<0.05），but there was no statistically significant difference between control group and observation group（P>0.05）. HDL-C，recurrence rate and case fatality rate of two groups was no statistical significance between before and after treatment （P>0.05）. Conclusion The effects of Erigeron Shengmai capsule combined western medicine on the seeondary prevention for isehemic stroke are better than pure western medicine.

[Key words] Erigeron Shengmai capsule；Isehemic stroke；Seeondary prevention；Effect

缺血性脑卒中具有发病率高、致残/致死率高及复发率高等特点，已位居威胁人类生命健康的三大疾病之首，给家庭和社会带来了沉重负担，尤其是我国步入老龄化社会后老年人口集聚增多，这一问题显得更加突出[1]。我国缺血性脑卒中二级预防水平相对较差，导致复发率较高，长期服用阿司匹林等抗血小板聚集药物是缺血性脑卒中二级……